A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2015
Price : $35 *
At a glance
- Drugs Velpatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 30 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Dec 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 10 Dec 2013 New trial record